Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

NCT02213744 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT02213744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02213744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 2/3
Overall status
Terminated
Start date
July 31, 2014
Completion date
June 30, 2017
Enrollment
113 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2 positive breast cancer